Overview

Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin
Pioglitazone